- Home
- NXN vs ICCC Comparison
NXN vs ICCC Comparison
Compare NXN & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXN
- ICCC
- Stock Information
- Founded
- NXN 1992
- ICCC 1982
- Country
- NXN United States
- ICCC United States
- Employees
- NXN N/A
- ICCC N/A
- Industry
- NXN Trusts Except Educational Religious and Charitable
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- NXN Finance
- ICCC Health Care
- Exchange
- NXN Nasdaq
- ICCC Nasdaq
- Market Cap
- NXN 44.9M
- ICCC 45.9M
- IPO Year
- NXN N/A
- ICCC 1987
- Fundamental
- Price
- NXN $11.66
- ICCC $5.50
- Analyst Decision
- NXN
- ICCC
- Analyst Count
- NXN 0
- ICCC 0
- Target Price
- NXN N/A
- ICCC N/A
- AVG Volume (30 Days)
- NXN 9.7K
- ICCC 10.0K
- Earning Date
- NXN 01-01-0001
- ICCC 02-25-2025
- Dividend Yield
- NXN 4.23%
- ICCC N/A
- EPS Growth
- NXN N/A
- ICCC N/A
- EPS
- NXN 0.24
- ICCC N/A
- Revenue
- NXN N/A
- ICCC $23,838,001.00
- Revenue This Year
- NXN N/A
- ICCC N/A
- Revenue Next Year
- NXN N/A
- ICCC N/A
- P/E Ratio
- NXN $48.42
- ICCC N/A
- Revenue Growth
- NXN N/A
- ICCC 46.37
- 52 Week Low
- NXN $10.64
- ICCC $3.34
- 52 Week High
- NXN $12.45
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- NXN 58.29
- ICCC 62.66
- Support Level
- NXN $11.26
- ICCC $4.86
- Resistance Level
- NXN $11.89
- ICCC $5.50
- Average True Range (ATR)
- NXN 0.09
- ICCC 0.35
- MACD
- NXN 0.04
- ICCC -0.01
- Stochastic Oscillator
- NXN 63.92
- ICCC 100.00
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.